HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target

HC Wainwright & Co. analyst Brandon Folkes has reiterated a Buy rating on Cardiol Therapeutics (NASDAQ: CRDL) and maintained a price target of $9 for the stock. No additional financial figures or strategic changes were mentioned in the article.